Analytical Data
-
Gene name
Carboxypeptidase B1/CPB1
- Application
-
Alternative Names
CPB; PCPB; PASP; Pancreas-specific protein
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P15086
-
Expression Region
Ala111~Tyr417
-
Molecular Weight
39kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Carboxypeptidase B1 (CPB1) is a pancreatic enzyme that plays a crucial role in protein digestion by cleaving basic amino acids from the carboxyl terminus of polypeptides. Its importance extends beyond digestion, as CPB1 is implicated in various physiological processes, including inflammation and cancer progression. The interest in recombinant CPB1 has surged due to its potential applications in biotechnology and medicine, such as drug development, enzyme therapy, and as a tool for protein engineering. Researchers aim to produce and characterize recombinant CPB1 to understand its structure-function relationship better and explore its therapeutic potential. Advances in recombinant DNA technology have enabled improved yields and functional activity of CPB1, facilitating its study in various assays. Additionally, investigating the enzyme’s kinetics, stability, and interaction with inhibitors could provide insights into its mechanism of action and pave the way for the design of CPB1-based interventions in diseases where this enzyme is dysregulated. Overall, recombinant CPB1 research holds promise for enhancing our understanding of enzymatic processes and developing novel therapeutic strategies.
